+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 13 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of lebrikizumab, a drug given by injection, in people aged 12 and older with chronic rhinosinusitis and nasal polyps who are also treated with intranasal corticosteroids. This phase 3 trial aims to improve symptoms like nasal congestion and polyp size while monitoring participant safety over about 18 months. Participants receive lebrikizumab injections on different schedules or placebo injections, all along with standard intranasal corticosteroid spray. Adolescents aged 12 to under 18 who weigh at least 40 kg are assigned to open-label lebrikizumab treatment. The study includes multiple groups receiving injections every 2, 4, or 8 weeks to compare outcomes. During the study, participants will undergo assessments including nasal congestion scoring, endoscopic evaluation of nasal polyps, sinus imaging, lung function tests, and symptom questionnaires from the start through 24 weeks. Safety and symptom changes are closely monitored, and the total study duration is approximately 18 months.

Age: 12Years +All GendersPhase 3
202 locations
M

Actively Recruiting

Researchers are evaluating mavorixafor, a drug being studied for people aged 12 and older who have congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorders. These conditions cause low neutrophil levels and lead to recurrent or serious infections. The study aims to show if mavorixafor can improve clinical outcomes and increase neutrophil counts, while also assessing its safety and tolerability. Participants will continue their current treatment during the study, which may include therapies like granulocyte-colony stimulating factor G-CSF, immunoglobulin replacement, antibiotics, or no active treatment. They will be randomly assigned to receive either mavorixafor or a placebo orally once daily for up to 52 weeks. The study uses a quadruple-blind design to compare these groups in parallel. During the trial, participants will have regular assessments to monitor infection rates and severity, neutrophil counts, antibiotic use, oral ulcers, and fatigue levels using questionnaires. An independent committee will review infections to ensure accuracy. Safety and treatment effects will be followed throughout the 52-week treatment period. The total participation may last until the study ends in late 2027.

Age: 12Years +All GendersPhase 3
114 locations
C

Actively Recruiting

This research aims to evaluate the effects of TAK-330 compared to standard four-factor prothrombin complex concentrate 4F-PCC in adults treated with Factor Xa inhibitors who need urgent surgery or invasive procedures. The study focuses on reversing anticoagulation caused by Factor Xa inhibitors and is a Phase 3, randomized, triple-blind trial sponsored by Takeda. Participants will be randomly assigned to receive either TAK-330 or the standard 4F-PCC. TAK-330 is given as a single intravenous infusion dose of 25 IUkg before surgery, with an optional additional 25 IUkg dose during surgery if needed, not exceeding a total of 50 IUkg or 5,000 IU. The standard 4F-PCC dose and infusion speed follow local protocols, with an additional dose allowed during surgery under the same maximum limits. These treatments are administered during hospitalization prior to surgery. During the study, participants will be hospitalized for the surgery and treatment administration, with assessments of hemostasis effectiveness at surgery end and 24 hours after treatment. Researchers will monitor blood product use, adverse events including thrombotic events, and participant survival up to 30 days after surgery. Follow-up will also include contact via telehealth or phone 30 days post-surgery to evaluate safety and outcomes. Total participation duration covers the hospital stay and the 30-day post-surgery monitoring period.

Age: 18Years +All GendersPhase 3
64 locations
P

Actively Recruiting

Researchers are evaluating the effects of felzartamab in adults with Immunoglobulin A nephropathy IgAN, a kidney disease caused by the buildup of abnormal IgA antibodies in the kidneys. This buildup leads to inflammation and damage, resulting in protein in the urine proteinuria. The study aims to learn how felzartamab affects proteinuria and kidney function compared to a placebo, while also assessing the safety and how the drug is processed by the body. Participants will be randomly assigned to receive either intravenous IV infusions of felzartamab or a placebo that contains no active medicine. The treatment period lasts for 24 weeks, followed by an 80-week follow-up period. Some participants with lower kidney filtration rates will be included in specific cohorts receiving either felzartamab or placebo. Overall, participants will have 17 study visits during about 2 years in the trial. During the study, participants will undergo various assessments including urine protein measurement, kidney function tests using estimated glomerular filtration rate eGFR, and monitoring for immune responses and adverse events. Blood samples will be collected to measure drug levels and antibodies against felzartamab. Safety will be monitored through vital signs, laboratory tests, physical exams, and ECGs. Researchers will evaluate changes from baseline up to 36 weeks for proteinuria and up to 104 weeks for kidney function and safety outcomes.

Age: 18Years +All GendersPhase 3
265 locations
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
S

Actively Recruiting

This research aims to evaluate the safety and effectiveness of the Hydrustent4 biodegradable hydrogel ureteral stent in adults with urinary lithiasis who have undergone surgery to remove ureteral or renal stones. The study will compare Hydrustent4 to a standard ureteral stent device to determine if it is at least as safe and effective in maintaining urine flow through the ureter after surgery. The trial includes both a pilot phase to explore initial safety and efficacy and a pivotal phase to confirm clinical performance. Participants will receive either the Hydrustent4 stent or a comparator ureteral stent after stone removal surgery. The Hydrustent4 device is designed to degrade naturally in the body, potentially avoiding the need for a second surgery to remove the stent, while the comparator is a conventional polyurethane double loop stent. The study will monitor the durability of the device for at least 24 hours and assess whether the device reduces urinary symptoms and prevents additional surgical procedures. During the 3-month follow-up period, participants will attend regular visits for assessments including questionnaires, imaging exams, and blood and urine tests to monitor recovery and device performance. Researchers will closely track safety through adverse events and device issues, evaluate urine drainage after stent placement, and assess symptoms related to the stents. The study will measure both technical success and tolerability of the devices throughout the treatment and follow-up phases.

Age: 18Years +All GendersPhase Not Applicable
4 locations
F

Actively Recruiting

Researchers are studying people with interstitial lung diseases ILD to understand how their ability to perform daily activities, called functional status, changes over time. The study aims to explore what causes declines in functional status, evaluate tools that measure this ability, gather patients perspectives through interviews, track progression over two years, and develop a combined index to predict mortality. ILD causes lung inflammation and scarring, leading to breathing difficulties and muscle weakness that affect daily functioning and quality of life. This observational study includes several tasks first, validating functional status measurement tools with assessments at baseline and one week later second, conducting interviews to capture patient experiences third, tracking functional status and health outcomes every six months for two years aligned with routine appointments and finally, using collected data to create a multidimensional index predicting mortality. Assessments involve physical tests, questionnaires, interviews, and clinical data collection. Participants will be involved in about 90-minute sessions for each assessment at designated hospitals. Researchers will collect data on muscle strength, physical activity, symptoms, quality of life, hospitalizations, and mortality. The primary outcome is measured by the Short Physical Performance Battery at multiple time points. Safety and health status are monitored throughout, with data analyzed to understand functional decline and its impact in ILD over time.

Age: 18Years +All Genders
1 location
E

Actively Recruiting

Researchers are evaluating a combination of oral decitabine and ivosidenib as a first-line treatment for adults with newly diagnosed acute myeloid leukemia AML who have an IDH1 R132 mutation. This study focuses on older adults aged 60 years and above, or adults aged 18 years and older with specific health conditions that make them unsuitable for standard intensive chemotherapy. The main goals are to assess the rates of complete remission and incomplete marrow recovery, as well as to monitor the occurrence and severity of any adverse events. Participants will receive treatment cycles lasting 28 days, consisting of oral ivosidenib taken daily for 28 days and oral decitabine-cedazuridine tablets taken once daily for the first 5 days of each cycle. During screening and the first two treatment cycles, hydroxyurea or cytarabine may be used to control high white blood cell counts. Those who achieve remission may be eligible for allogeneic stem cell transplantation, after which they can resume ivosidenib treatment from day 60 post-transplant, continuing for up to two years. Throughout the study, participants will have regular assessments to monitor their response to treatment, including disease progression and any side effects. Those undergoing transplant will have additional evaluations before and after the procedure, including minimal residual disease statistics. The researchers will measure remission rates over three years, along with overall survival, event-free survival, quality of remission, and early mortality. Participants are followed until disease progression, unacceptable toxicity, withdrawal, or study completion, expected by April 2029.

Age: 18Years +All GendersPhase 2
20 locations
P

Actively Recruiting

Researchers are evaluating treatments for advanced breast cancer that is hormone receptor HR-positive and HER2-low or ultralow, classified as non-luminal subtype by gene expression profiling PAM50. This phase II international study compares trastuzumab deruxtecan T-DXd with a physicians choice of CDK46 inhibitor plus endocrine therapy ET to see which better prolongs progression-free survival in these patients. Participants will be randomly assigned to receive either T-DXd at 5.4 mgkg body weight by intravenous infusion every 21 days or one of several CDK46 inhibitors palbociclib, ribociclib, or abemaciclib combined with an endocrine therapy fulvestrant, letrozole, anastrozole, or exemestane chosen by their doctor. Treatment will continue in 21-day cycles, and the study will assess outcomes over up to 25 months. During the study, participants will undergo regular assessments including imaging scans to evaluate tumor response and progression. Researchers will monitor progression-free survival, overall survival, response rates, quality of life, and safety through adverse event tracking. Follow-up and treatment adherence will be closely observed to understand the effects and tolerability of these therapies in this specific breast cancer subtype.

Age: 18Years +All GendersPhase 2
79 locations
P

Actively Recruiting

Researchers are studying whether adding navtemadlin to ruxolitinib treatment can provide more benefit than ruxolitinib alone for adults with Myelofibrosis who have not responded well to ruxolitinib by itself. This Phase 3 trial includes patients who are new to JAK inhibitor treatment and have a confirmed diagnosis of primary or post-polycythemia vera or post-essential thrombocythemia Myelofibrosis. The study aims to assess improvements in spleen size and symptom reduction over 24 weeks, as well as long-term outcomes like disease progression and overall survival. Participants first receive ruxolitinib alone during a run-in period to identify those with suboptimal response. Those qualifying are randomly assigned in a 21 ratio to receive either navtemadlin or a placebo as an add-on to their ongoing ruxolitinib. Navtemadlin or placebo is taken orally once daily for 7 days followed by 21 days off in 28-day cycles, while ruxolitinib is taken twice daily continuously. The study is double-blinded so neither participants nor researchers know which add-on treatment is given. During the trial, participants will undergo evaluations including spleen volume measurements and symptom assessments at 24 weeks. They will be monitored for disease progression and survival for up to 8 years. The study includes regular check-ups to track side effects, treatment adherence, and overall health status. These detailed assessments help researchers understand the potential benefits and safety of adding navtemadlin for patients with Myelofibrosis.

Age: 18Years +All GendersPhase 3
215 locations

1-10 of 13

1